Literature DB >> 3561445

Demyelination in vivo by Guillain-Barré syndrome and other human serum.

M J Brown, J L Rosen, R P Lisak.   

Abstract

Serum from patients with acute inflammatory polyneuropathy (the Guillain-Barré syndrome, GBS) demyelinates peripheral nerves in vivo more intensely than control human serum. To clarify the processes leading to demyelination we injected rat sciatic nerves with serum from GBS and control subjects in the presence of complement and examined the sequential morphologic changes over 7 days. One day after injection, five of six GBS sera but none of seven control sera caused vesicular demyelination; 3-5 days after injection both GBS and control sera produced macrophage-mediated demyelination. These observations suggest that GBS serum can initiate acute myelin injury through a humoral mechanism that is disease associated. This response appears to be distinct from delayed cell-mediated serum-induced demyelination that is not disease specific.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3561445     DOI: 10.1002/mus.880100310

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  4 in total

1.  Unmyelinated fibers in sural nerve biopsies of chronic inflammatory demyelinating polyneuropathy.

Authors:  E Gibbels; M Kentenich
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

2.  IgG immunoadsorption in experimental allergic neuritis: effect on antibody levels and clinical course.

Authors:  G K Harvey; K Schindhelm; J D Pollard
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-07       Impact factor: 10.154

3.  A prospective study of acute idiopathic neuropathy. III. Immunological studies.

Authors:  J B Winer; I A Gray; N A Gregson; R A Hughes; S Leibowitz; P Shepherd; W A Taylor; V Yewdall
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-05       Impact factor: 10.154

Review 4.  Inflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention.

Authors:  Eroboghene E Ubogu
Journal:  Acta Neuropathol       Date:  2015-08-12       Impact factor: 17.088

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.